CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing innovative biological blockers targeting the P2Y6 receptor to enhance immunotherapy for pancreatic cancer. By understanding metabolic pathways that contribute to immune suppression in tumors, the research aims to create effective treatments with minimal side effects.
The introduction of immunotherapy revolutionized cancer treatment, nevertheless, pancreatic cancer is still an omen of death with a dismal 5-year survival rate.
Improvement of the current therapies for pancreatic cancer patients is thus an unmet medical need.
The research we performed for the ERC CoG ImmunoFit identified novel metabolic pathways shaping the tumor microenvironment toward immunosuppression.
Our latest publication in Nature Cancer characterized the CDA-UDP-P2Y6 axis as a major dete…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
